SCHEMBL2393053

SCHEMBL2393053

O=C(O)c1ccc(NC(=O)c2cc3c4c(c2)CCCCC4CCCC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HDAC3 O15379 2/20 0.51
HDAC11 Q96DB2 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
DEGS1 O15121 1/20 0.51
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
FFAR1 O14842 1/20 0.48
RXFP1 Q9HBX9 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
NFKB1 P19838 1/20 0.47
HTT P42858 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394763 0.96 MEN1 (0.54) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL2394945 0.91 RAB9A (0.51) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL2394947 0.86 RAB9A (0.52) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL2393644 0.86 NPC1 (0.50) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL2393108 0.84 KMT2A (0.59) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL830021 0.84 KMO (0.42) MEN1KMT2ACNR1CNR2NPC1
SCHEMBL2392613 0.83 CPT2 (0.45) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL2394623 0.83 RARA (0.48) KMT2ANPC1RAB9ATP53SMN1; SMN2
SCHEMBL2396155 0.82 PTPN1 (0.51) MEN1KMT2AHDAC3HDAC11HDAC8
SCHEMBL2396270 0.82 HCAR3 (0.56) DEGS1NPC1RAB9ARARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861640-B2 Medicament for treatment of Alzheimer's disease KEMPHYS LTD. (JP) 2018-01-09 US claimed
US-20160206624-A1 MEDICAMENT FOR TREATMENT OF ALZHEIMER'S DISEASE KEMPHYS LTD. (JP) 2016-07-21 US claimed
US-9861640-B2 Medicament for treatment of Alzheimer's disease KEMPHYS LTD. (JP) 2018-01-09 US disclosed
US-20160206624-A1 MEDICAMENT FOR TREATMENT OF ALZHEIMER'S DISEASE KEMPHYS LTD. (JP) 2016-07-21 US disclosed
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG MEN1 3029/4885KMT2A 1560/4885HDAC3 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.